Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-Infectives Have Blockbuster Future Despite Personalized Medicine

Executive Summary

Anti-infectives have the potential to remain top-selling products in the future even as personalized medicine curtails the number of therapies achieving blockbuster status, Lehman Brothers Vice Chairman Frederic Frank said

You may also be interested in...



Novartis Would Get Anti-Infective, Oncologic Pipeline Drugs In Chiron Deal

Novartis' proposed acquisition of Chiron would give the company anti-cancer and anti-infective molecules to complement its oncologic portfolio and infectious disease pipeline

Novartis Would Get Anti-Infective, Oncologic Pipeline Drugs In Chiron Deal

Novartis' proposed acquisition of Chiron would give the company anti-cancer and anti-infective molecules to complement its oncologic portfolio and infectious disease pipeline

Biotech Exit Strategy Of Choice Is Acquisition, Not IPO, Investor Says

Venture capital firms are increasingly shaping biotech companies to look like acquisition prospects from the outset, rather than candidates for initial public offerings, according to one investor's analysis

Related Content

Topics

UsernamePublicRestriction

Register

PS046187

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel